Urodelia, a Toulouse (France) biotech company specialized in personalised anti-cancer therapeutic vaccine, and 4P-Pharma, a Lille (France) biotech company specialised in human and animal drug development, are pleased to announce that they established a business development partnership. As an exclusive partner, 4P-Pharma will seek strategic opportunities in Animal Health for the licensing-out of Urodelia’s Apa.vac® anticancer therapeutic vaccine.
4P-Pharma team wishes you a happy holidays season. We believe that with hard work, imagination and a strong team spirit everything is achievable, and the dream that you were pursuing becomes right there for you to grab!
4P-Pharma Team will be attending the upcoming Biofit 2018 conference in Lille December 4-5th. To learn more about possible partnerships, co-development and our pipeline, contact us via the partnering platform or get in touch with our Business Developer Roselina Lam at roselina(at)4p-pharma.com.
Our collaboration with Elsevier’s The Hive program continues with a new blog post entry! In our previous blog post we detailed how Elsevier’s suite of R&D solutions have been helping us in boosting our Research (Read it here). This time we focus on our business model of partnerships and co-development to detect and develop promising technologies in the field of cancer and inflammatory diseases.